Contrasting Ocular Therapeutix (NASDAQ:OCUL) & Jaguar Animal Health (NASDAQ:JAGX)
by Teresa Graham · The Cerbat GemOcular Therapeutix (NASDAQ:OCUL – Get Free Report) and Jaguar Animal Health (NASDAQ:JAGX – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.
Risk & Volatility
Ocular Therapeutix has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, Jaguar Animal Health has a beta of -0.11, suggesting that its share price is 111% less volatile than the S&P 500.
Earnings & Valuation
This table compares Ocular Therapeutix and Jaguar Animal Health”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ocular Therapeutix | $51.95 million | 29.47 | -$265.94 million | ($1.42) | -4.91 |
| Jaguar Animal Health | $27.79 million | 0.11 | -$53.43 million | ($3,731.33) | -0.00 |
Jaguar Animal Health has lower revenue, but higher earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Jaguar Animal Health, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings and recommmendations for Ocular Therapeutix and Jaguar Animal Health, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ocular Therapeutix | 1 | 1 | 8 | 1 | 2.82 |
| Jaguar Animal Health | 1 | 0 | 0 | 0 | 1.00 |
Ocular Therapeutix presently has a consensus target price of $23.33, suggesting a potential upside of 234.77%. Given Ocular Therapeutix’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Ocular Therapeutix is more favorable than Jaguar Animal Health.
Profitability
This table compares Ocular Therapeutix and Jaguar Animal Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ocular Therapeutix | -579.10% | -59.89% | -45.99% |
| Jaguar Animal Health | -187.88% | N/A | -131.45% |
Institutional & Insider Ownership
59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 12.0% of Jaguar Animal Health shares are held by institutional investors. 3.1% of Ocular Therapeutix shares are held by insiders. Comparatively, 0.1% of Jaguar Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Ocular Therapeutix beats Jaguar Animal Health on 11 of the 15 factors compared between the two stocks.
About Ocular Therapeutix
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company’s sustained-release hydrogel in combination with Regeneron’s large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
About Jaguar Animal Health
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.